Version 2.1.0.0 CRISP Logo CRISP Homepage Help for CRISP Email Us

Abstract

Grant Number: 1R43AI052909-01
PI Name: CHAPPLE, JOANNE P.
PI Email: jchapple@cubist.com
PI Title:
Project Title: Inhibitors of Bacterial Undecaprenyl DiphosphateSynthase

Abstract: DESCRIPTION (provided by applicant): The recent emergence of Gram positive bacteria which are resistant to many current antiinfective therapies presents a challenge to the pharmaceutical industry: New classes of inhibitory molecules are needed which are substantially different than the previous generation of drugs. This need is heightened in the wake of recent occurence of Bacillus anthracis infections, and the need for additional antiinfectives to treat anthrax. Cubist Pharmaceuticals is addressing this need by using a target-based drug discovery process that centers its efforts on bacterial targets whose activity has not yet been targeted by an antiinfective. In this proposal, we present a clear-cut route for identifying leads for a broad-spectrum(B. anthracis -inclusive) antiinfective therapy through a target-based high throughput screen of bacterial Undecaprenyl diphosphate synthase (Upps).

Thesaurus Terms:
Bacillus anthracis, alkyltransferase, antibacterial agent, antiinfective agent, bacterial protein, drug discovery /isolation, phosphorus compound
drug resistance, enzyme inhibitor
bioterrorism /chemical warfare, high throughput technology

Institution: CUBIST PHARMACEUTICALS, INC.
65 HAYDEN AVE
LEXINGTON, MA 02421
Fiscal Year: 2002
Department:
Project Start: 01-AUG-2002
Project End: 30-JUN-2003
ICD: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
IRG: ZRG1


CRISP Homepage Help for CRISP Email Us